Recently, based on the OPB sequence and the YY1 binding site on EZH2, we developed two peptides that could disrupt the regulation of oncoproteins by YY1 and consequently reduce the growth of xenograft tumors generated by triple negative breast cancer cells [20,21], which validated YY1 as a cancer therapeutic target. This evidence concerns the gene EZH2 and cancer.